GRPR and prostate carcinoma: Based on the GRPR overexpression in the early stages of the disease as opposed to healthy or hyperplastic surrounding tissue, GRPR-directed radiopharmaceuticals are expected to play a significant role in the management of prostate cancer, especially in primary and oligometastatic stage (Beer et al. 2012; Mansi et al. 2021; Patel et al. 2006; Rinne et al. 2021).